Cefpodoxime/Orelox from Sanofi is a third-generation cephalosporin antibiotic used similarly to cefixime in the treatment of susceptible infections. It is given by mouth as the proxetil ester, which is hydrolysed on absorption to cefpodoxime. Doses are expressed in terms of the equivalent amount of cefpodoxime. 130 mg of cefpodoxime proxetil is approximately equivalent to 100 mg of cefpodoxime. Absorption may be enhanced if cefpodoxime proxetil is given with food. The usual adult dose is
- 100 to 200 mg every 12 hours for respiratory-tract and urinary-tract infections.
- A dose of 200 or 400 mg every 12 hours may be used for skin infections.
- In children doses of 8 to 10 mg/kg daily may be given in 2 divided doses, up to a maximum of 200 mg daily for respiratory-tract infections or 400 mg daily for otitis media or sinusitis.
The interval between doses of cefpodoxime may need to be extended in patients with renal impairment.
For uncomplicated gonorrhoea, a single dose of 200 mg may be given.
Adverse Effects and Precautions
The most frequently reported adverse effects of cefpodoxime are gastrointestinal disturbances, especially diarrhoea. Othersiwe Orelox is well tolerated unless if the user is allergic to it.
Absorption of cefpodoxime is decreased by antacids or histamine H2-receptor antagonists. Probenecid reduces the renal excretion of cefpodoxime.